SITC Archive Library

2014 Workshop on Combination Immunotherapy: Where Do We Go From Here?
November 6, 2014
Gaylord National Hotel & Convention Center National Harbor, MD

Program Organizers
Anna Carrizosa Anderson, PhD - Harvard Medical School
Drew M. Pardoll, MD, PhD - Johns Hopkins University
Mario Sznol, MD - Yale University Dario A. A. Vignali, PhD - University of Pittsburgh

Program Summary
From the Society for Immunotherapy of Cancer (SITC), these enduring materials from the 2014 Workshop on Combination Immunotherapy: Where Do We Go From Here? identifies the current challenges to implementation of combination immune-based therapies across multiple cancer indications and to identify potential solutions to improve the rational application of immunotherapy. Immune-profiling of the tumor microenvironment by multiple different approaches is currently being pursued as a means to guide the development and clinical application of combination immunotherapies. Immune-profiling prior to treatment may hold the key to elucidation of biomarkers predictive of response while immune-profiling of patients undergoing treatment may hold the key for identifying biomarkers indicative of favorable clinical response, thus providing a means for early intervention and modification of treatment regimens in patients who may not be responding. By participating in the workshop, participants interacted with clinicians and scientists at the forefront of the cancer immunotherapy field. Participants learned about the current barriers, the outstanding unaddressed questions, the current approaches and technologies being employed in the field, and future directions. Most importantly, participants had the opportunity to connect with leaders in the field to spark new collaborations to push the field forward.

Target Audience
The target audience for this program included basic scientists and clinical investigators from academic institutions, industry, and regulatory agencies. The audience included clinicians, translational and basic researchers, graduate students, and postdoctoral fellows involved in cancer research.     

#Biomarkers #ClinicalTrials #Melanoma #PresentationSlides #Video #AnnualMeeting
#SITC #CombinationTherapy #ImmuneCheckpointInhibitors #Ipilimumab #Nivolumab #Cytokines #Clinician #Industry
#Oncologist #Researcher #2014